PT-141 (Bremelanotide): The Peptide That Works on the Brain, Not the Blood Vessels
PT-141 is the only FDA-approved treatment for sexual dysfunction that works through the central nervous system rather than vascular mechanisms. Here's what you need to know about how it works and what the research shows.
Sexual dysfunction affects millions of people, yet treatments have historically focused almost exclusively on vascular mechanisms — drugs like sildenafil (Viagra) work by increasing blood flow to the genitals. PT-141 takes an entirely different approach, acting on the brain's melanocortin system to initiate sexual desire from the top down.
What Is PT-141?
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that is an analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds to melanocortin receptors — particularly MC3R and MC4R — in the central nervous system.
It was FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first treatment for female sexual dysfunction that works centrally rather than hormonally or vascularly.
Importantly, PT-141 was originally derived from Melanotan II — a peptide studied for tanning — when researchers noticed that a significant number of study participants reported spontaneous and prolonged erections and increased sexual desire as a side effect.
How Does PT-141 Work?
PT-141 activates melanocortin-3 and melanocortin-4 receptors in the hypothalamus and limbic system — brain regions directly involved in sexual motivation, arousal, and reward.
Unlike PDE5 inhibitors (Viagra, Cialis) which require sexual stimulation to trigger a vascular cascade, PT-141 works at the level of desire and motivation itself. It appears to activate dopaminergic neurons in the mesolimbic pathway, increasing the brain's drive toward sexual activity.
This mechanism has several clinical implications:
- It works in men and women
- It does not require prior sexual stimulation
- It does not depend on vascular function (and therefore may work in cases where vascular ED treatments don't)
- It addresses desire and arousal, not just the mechanical aspects of sexual function
What Does the Research Show?
In women with HSDD. The RECONNECT trials (two Phase 3 studies) enrolled 1,247 premenopausal women with HSDD. Compared to placebo, bremelanotide produced statistically significant improvements in:
- Satisfying sexual events per month (+0.7 events vs +0.4 for placebo)
- Female Sexual Function Index desire domain score
- Female Sexual Distress Scale score (reduction in distress from low desire)
In men with erectile dysfunction. Earlier Phase 2 trials tested PT-141 in men with ED, including those who had not responded to sildenafil. PT-141 produced successful erections in approximately 75-80% of attempts in men where sildenafil had failed, demonstrating that its central mechanism bypasses the vascular limitations that restrict PDE5 inhibitors.
In women with sexual arousal disorder. Small studies have found PT-141 increases genital arousal (measured by vaginal photoplethysmography) and subjective sexual arousal in women with arousal disorders.
Dosing and Administration
The FDA-approved protocol for HSDD (Vyleesi):
- 1.75 mg subcutaneous injection into the abdomen or thigh
- Administered at least 45 minutes before anticipated sexual activity
- No more than once per 24 hours; no more than once per week recommended
Off-label research protocols have explored doses from 0.5 mg to 2.0 mg, with some finding that lower doses (0.75-1.0 mg) produce meaningful effects with fewer side effects.
Side Effects
The most common side effect is nausea, reported by approximately 40% of patients in clinical trials. This is typically mild to moderate and resolves within 1-2 hours. Pre-treatment with ondansetron (anti-nausea medication) significantly reduces this.
Other notable effects:
- Flushing (warm sensation, particularly in the face and upper body) — ~20% of patients
- Transient blood pressure increase lasting 8-12 hours (clinical significance monitored)
- Headache
- Spontaneous erections in males at higher doses
The transient blood pressure increase means PT-141 is contraindicated in patients with cardiovascular disease or uncontrolled hypertension.
The Bottom Line
PT-141 represents a genuinely novel approach to sexual dysfunction — one that addresses desire and arousal at the neurological level rather than simply facilitating blood flow. For individuals who have found little benefit from conventional treatments or who specifically experience low desire rather than mechanical dysfunction, PT-141's central mechanism of action makes it a scientifically compelling and clinically validated option.
About the Author
KnowYourPeptide Research Team
KnowYourPeptide Research Team
Content produced by the KnowYourPeptide research and editorial team. All articles are written from peer-reviewed primary literature and reviewed for scientific accuracy by credentialed researchers and a board-certified physician before publication.
Meet the full editorial teamMedically Reviewed by Dr. Amanda Reid, MD
This article has been reviewed by Dr. Amanda Reid, MD (Board-Certified Internal Medicine), Know Your Peptide Medical Advisor, for scientific accuracy, safety information, and appropriate clinical context. Learn about our review process.